Ulrich Lehner - Novartis AG Insider

Novartis AG -- Mexico Stock  

MXN 1,530  0.00  0.00%

Vice Chairman of the Board of Directors, Non-Executive Director

Age: 68  Chairman Since 2006  MBA    
Ulrich Lehner, Ph.D., was Vice Chairman of the Board of Directors and NonExecutive Director of Novartis AG since 2006. He serves as Chairman of the Corporationrationrationrate Governance and Nomination Committee of the Company, as well as Member of the Audit and Compliance Committee, the Risk Committee, the Chairman?s Committee, and the Compensation Committee. He has acted as NonExecutive Director and Member of the Board of Directors of the Company since 2002. He has also cowoorked with the Audit Committee. From 1975 to 1981, he was an auditor with KPMG Deutsche TreuhandGesellschaft AG in Duesseldorf. In 1981, he joined Henkel KGaA. After heading the Controlling Department of Fried. Krupp GmbH in Germany from 1983 to 1986, Prof. Lehner returned to Henkel as Finance Director. From 1991 to 1994, he headed Henkel AsiaPacific Ltd in Hong Kong, and from 1995 to 2000, served as Executive Vice President, Finance/Logistics, of Henkel KGaA. From 2000 to 2008, Prof

Management Efficiency

The company has return on total asset (ROA) of 4.39 % which means that it generated profit of $4.39 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 10.33 % meaning that it generated $10.33 on every $100 dollars invested by stockholders.
The company has accumulated 28.53 B in total debt with debt to equity ratio (D/E) of 38.4 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Novartis AG has Current Ratio of 1.19 suggesting that it may not be capable to disburse its financial obligations in time and when they become due.

Entity Summary

Novartis AG (NVSN) is traded on Mexico Stock Exchange in Mexico. and employs 37 people.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Novartis AG to your portfolio

Top Management

Novartis AG Leadership Team
Joerg Reinhardt, Chairman, Ph.D
Ton Buechner, Director, MBA
Paul Hudson, CEO
Verena Briner, Executive
Brian McNamara, Executive
Michele Galen, Executive
Charles Sawyers, Executive, Ph.D
Steven Baert, Executive, MBA
Dimitri Azar, Director, MBA
Richard Francis, Executive
Frans Houten, Director
Nancy Andrews, Director, Ph.D
Enrico Vanni, Director, MBA
Pierre Landolt, Director
Elizabeth Doherty, Director
Andre Wyss, President
Bruno Strigini, CEO
Erwin Vanhaecke, Executive, Ph.D
Vasant Narasimhan, Executive
Michael Ball, CEO, MBA
Jeffrey George, Executive, MBA
Mark Fishman, President, Ph.D
Charlotte PamerWieser, Executive
Peter Kornicker, Executive, Ph.D
Andreas Planta, Director
Joseph Jimenez, CEO, MBA
Samir Shah, Executive
Ulrich Lehner, Chairman, MBA
William Winters, Executive, MBA
David Epstein, Executive, MBA
Ann Fudge, Director, MBA
Srikant Datar, Director, MBA
George Gunn, Executive, Ph.D
Paul Arkel, Executive
James Bradner, President
Felix Ehrat, Executive
Harry Kirsch, CFO
Andrin Oswald, Executive, Ph.D

Stock Performance

Novartis AG Performance Indicators